Esophageal And Gastric Cancer

More documents

Recommendations

Info

ASCO GI: Advanced <strong>Esophageal</strong> <strong>Cancer</strong> Benefits from Multimodality Neoadjuvant Therapy Patients with locally advanced esophageal and gastric cancer had a high rate of pathologic complete response and resectability with neoadjuvant cetuximab (Erbitux) and chemoradiation
ChemoRT plus Erbitux • Complete pathologic responses in 11 of 44 (25%) patients • Near-complete pathologic response (microscopic residuals) in eight patients (18%) • Clinical/pathologic partial responses in 10 patients (23%) • Stable disease in 15 patients (34%)
Page 1: Esophageal and Gastric Cancer: Upda
Page 4 and 5: Esophageal Cancer • Epidemiology:
Page 6 and 7: Timing of Oncology Treatment Neoadj
Page 8 and 9: Neoadjuvant Therapy for Esophageal
Page 10 and 11: Preoperative Chemoradiation of Esop
Page 12 and 13: Trimodality Trial (CALGB 9781) •
Page 14 and 15: Trimodality Trial • Conclusion: l
Page 16 and 17: Localized Esophageal Cancer: • RT
Page 18 and 19: New Agents For Combined Modality Tr
Page 20 and 21: Treatment: Metastatic Disease •Pr
Page 22 and 23: Chemotherapy for Advanced Esophagea
Page 24 and 25: Gastric Cancer • Epidemiology: M:
Page 26 and 27: Gastric Cancer 1930-1997 Age-adjust
Page 28 and 29: Neoadjuvant Question in Gastric Can
Page 30 and 31: Feb 20, 2009 - chemotherapy alone v
Page 32 and 33: Treatment of Localized Disease •
Page 34 and 35: Unresectable Gastric Cancer • Sur
Page 36 and 37: New Drugs in the Treatment of Advan
Page 38 and 39: Taxotere in Advanced Gastric Cancer
Page 40 and 41: Phase III Study Comparing Capecitab
Page 42 and 43: OXALIPLATIN • Less anemia • Les
Page 44 and 45: S1: Promising Drug under Investigat
Page 46 and 47: ECOG/CALGB 80403
Page 50: ASCO GI: Nutritional Support May Im

Esophageal And Gastric Cancer

Create successful ePaper yourself

Delete template?

Save as template?